Ketamine for Depression

If you are living with depression that has not responded to traditional antidepressants, you already know the frustration of waiting weeks for a medication to work, only to find it does not help. Treatment-resistant depression (TRD) affects roughly one-third of the 280 million people worldwide who experience depressive disorders, leaving many patients feeling as though they have exhausted their options. Ketamine therapy represents a fundamentally different approach, one that can produce meaningful relief within hours rather than weeks.

Over the past two decades, ketamine has emerged as one of the most significant breakthroughs in psychiatry. What was once primarily known as a surgical anesthetic has become a powerful tool for treating depression that other medications cannot reach. In this comprehensive guide, we will walk you through the science, the clinical evidence, and the practical realities of ketamine treatment for depression.

Understanding Depression and Treatment Resistance

Depression is far more than ordinary sadness. Major depressive disorder (MDD) is a medical condition characterized by persistent low mood, loss of interest in activities, changes in sleep and appetite, difficulty concentrating, fatigue, feelings of worthlessness, and in severe cases, thoughts of death or suicide. The World Health Organization ranks depression as a leading cause of disability worldwide.

What Makes Depression "Treatment-Resistant"

Treatment-resistant depression is generally defined as depression that has not responded adequately to at least two different antidepressant medications taken at adequate doses for sufficient duration, typically 6-8 weeks each. By this definition, approximately 30% of people with MDD have treatment-resistant depression.¹

The conventional approach to depression treatment follows a sequential model: start with one class of antidepressant, wait several weeks, assess response, switch or augment if needed, and repeat. This process can take months or even years. For patients with TRD, each failed trial can deepen hopelessness and erode confidence that effective treatment exists.

The Monoamine Hypothesis and Its Limitations

For decades, depression research focused almost exclusively on the monoamine hypothesis, which attributes depression to deficiencies in serotonin, norepinephrine, or dopamine. This model gave us SSRIs (selective serotonin reuptake inhibitors), SNRIs, tricyclics, and MAOIs, all of which work by modulating these neurotransmitters.

While these medications help many people, their limitations are significant. They take weeks to work, produce meaningful improvement in only about 50-60% of patients on first trial, and carry side effects including weight gain, sexual dysfunction, and emotional blunting that lead many patients to discontinue treatment.⁸

Ketamine challenges this paradigm entirely. Rather than targeting monoamines, ketamine acts on the glutamate system, opening an entirely new avenue for treating depression.

How Ketamine Treats Depression

The NMDA Receptor and Glutamate System

Ketamine is an NMDA (N-methyl-D-aspartate) receptor antagonist. The NMDA receptor is a type of glutamate receptor found throughout the brain. Glutamate is the most abundant excitatory neurotransmitter in the central nervous system, and the glutamate system plays a crucial role in synaptic plasticity, the brain's ability to form and strengthen connections between neurons.⁸

When ketamine blocks NMDA receptors, it triggers a cascade of downstream effects that ultimately enhance synaptic function. Here is how this process works:

1. NMDA receptor blockade on inhibitory interneurons leads to a transient surge of glutamate release
2. AMPA receptor activation by the increased glutamate stimulates intracellular signaling pathways
3. BDNF release (brain-derived neurotrophic factor), a protein critical for neuron growth and survival, increases rapidly
4. mTOR pathway activation promotes the synthesis of synaptic proteins needed to build new connections⁹
5. Synaptogenesis occurs within hours, with new dendritic spines forming and previously weakened synaptic connections being restored

Neuroplasticity: Rewiring the Depressed Brain

Depression is associated with significant structural changes in the brain. Chronic stress and depression cause dendritic atrophy, a shrinking and retraction of the branching structures that neurons use to communicate with each other, particularly in the prefrontal cortex and hippocampus.⁷

Ketamine appears to rapidly reverse these changes. Brain imaging studies have shown that a single ketamine infusion can increase synaptic density in the prefrontal cortex within 24 hours. This rapid structural repair may explain why ketamine works so much faster than traditional antidepressants, which achieve their effects through gradual neuroplasticity over weeks.⁵

Beyond NMDA: Additional Mechanisms

Research continues to uncover additional mechanisms through which ketamine exerts its antidepressant effects:

• Opioid receptor interaction: Some evidence suggests ketamine's antidepressant action may partly involve the opioid system, though this remains debated
• Anti-inflammatory effects: Ketamine has been shown to reduce neuroinflammation, which is increasingly recognized as a factor in depression
• Default mode network modulation: Ketamine appears to reset activity patterns in the default mode network, a brain circuit associated with rumination and self-referential negative thinking

Research Evidence

The Zarate 2006 Breakthrough

The seminal study that launched modern ketamine research for depression was published by Carlos Zarate Jr. and colleagues at the National Institute of Mental Health in 2006. In this randomized, placebo-controlled, double-blind crossover study, 18 patients with treatment-resistant depression received either a single IV ketamine infusion (0.5 mg/kg over 40 minutes) or saline placebo.¹

The results were remarkable:

• 71% of patients showed significant improvement within 24 hours of ketamine infusion
• 29% achieved full remission within one day
• 35% maintained response at one week
• Improvement began within 2 hours of the infusion
• The magnitude of improvement was substantial: a 14-point average drop on the Hamilton Depression Rating Scale

This study established the proof of concept that a single dose of an NMDA antagonist could produce rapid antidepressant effects in patients who had failed other treatments.

The Murrough 2013 Multisite Trial

Building on the Zarate findings, Murrough and colleagues conducted the first large, multisite, randomized controlled trial comparing ketamine to an active placebo (midazolam, a benzodiazepine that mimics some of ketamine's sedative effects without its antidepressant properties).²

Key findings from this pivotal trial:

• 64% of ketamine patients responded compared to 28% with midazolam
• The response rate difference was statistically significant and clinically meaningful
• Response was defined as a 50% or greater reduction in Montgomery-Asberg Depression Rating Scale (MADRS) scores
• Effects emerged within 24 hours and peaked at approximately 7 days

The use of midazolam as an active placebo was methodologically important. Because both substances produce noticeable psychoactive effects, this design controlled for the possibility that ketamine's benefits were simply due to patients knowing they received an active drug.

The Singh 2016 Suicidal Ideation Study

One of ketamine's most clinically important applications is in patients with active suicidal ideation. Singh and colleagues conducted a randomized, double-blind study examining ketamine's effect on suicidal thinking in 80 patients with treatment-resistant depression and clinically significant suicidal ideation.⁴

Results demonstrated:

• Significant reduction in suicidal ideation within 4 hours of infusion
• Effects on suicidal thinking were partly independent of improvements in overall depression
• The rapid timeline makes ketamine uniquely valuable in psychiatric emergencies
• This study contributed to the FDA's 2020 approval of Spravato for MDD with suicidal ideation

Meta-Analyses and Real-World Evidence

Beyond individual trials, multiple meta-analyses have confirmed ketamine's efficacy. A comprehensive 2022 systematic review of real-world effectiveness data found that ketamine maintains its antidepressant effects outside of controlled clinical trial settings, with response rates of 55-70% in clinical practice.¹⁰

Treatment Options for Depression

Ketamine therapy for depression is available in several forms, each with distinct advantages and considerations.

IV Ketamine Infusions

IV (intravenous) ketamine is the most extensively studied form for depression. The standard protocol involves:

• Dose: 0.5 mg/kg infused over 40 minutes
• Initial series: 6 infusions over 2-3 weeks (typically Monday-Wednesday-Friday)
• Maintenance: Every 2-6 weeks as needed, based on symptom recurrence
• Setting: Outpatient clinic with medical monitoring

Learn more about IV ketamine infusions

Spravato (Esketamine Nasal Spray)

Spravato is the FDA-approved nasal spray form containing esketamine (the S-enantiomer of ketamine):

• Dose: 56 mg or 84 mg self-administered under supervision
• Schedule: Twice weekly for the first month, then weekly, then every 1-2 weeks
• Requirement: Must be taken with an oral antidepressant
• Setting: Certified healthcare facility (REMS program requires 2-hour post-dose monitoring)

Learn more about Spravato

Other Delivery Methods

Additional routes include intramuscular injections, sublingual tablets, and compounded nasal sprays. While less studied than IV for depression specifically, these methods offer alternatives that may be more accessible or affordable for some patients.

*Response rates for SSRIs/SNRIs and Tricyclics are for TRD patients specifically (after at least 2 prior medication failures), not first-line use.

What to Expect During Treatment

Before Your First Infusion

Your journey typically begins with a comprehensive psychiatric evaluation. A qualified provider will review your depression history, previous treatments, current medications, and overall health to determine whether ketamine is appropriate for you.

Preparation steps include:

• Fasting for 4-6 hours before your appointment (to reduce nausea risk)
• Arranging transportation home (you cannot drive for 24 hours after treatment)
• Adjusting certain medications as directed by your provider
• Setting intentions for your treatment experience

During the Infusion

A standard IV ketamine infusion for depression lasts approximately 40 minutes. Throughout the process:

• You will be seated in a comfortable recliner in a calm, dimly lit treatment room
• A nurse or medical professional will start the IV line and begin the infusion
• Vital signs (blood pressure, heart rate, oxygen saturation) are monitored continuously
• You may experience dissociative effects: feeling detached from your body, altered sense of time, visual or auditory changes
• Many patients describe the experience as dreamlike or meditative
• A clinician remains nearby throughout the session

After Treatment

Following the infusion, you will typically rest in the clinic for 30-60 minutes until the acute effects have subsided. Common post-treatment experiences include:

• Mild drowsiness or fatigue for a few hours
• A sense of lightness or emotional relief that may emerge within hours
• Some patients notice improvement the same evening; for others, changes become apparent over the next 1-2 days
• It is normal not to feel dramatic changes after a single infusion, as the full therapeutic effect often builds across the series

Read our complete guide to what to expect during ketamine therapy

Candidate Screening and Contraindications

Who Benefits Most

Ketamine therapy for depression is most appropriate for:

• Adults with treatment-resistant depression (failed 2 or more adequate antidepressant trials)
• Patients with major depressive disorder and active suicidal ideation requiring rapid intervention
• Individuals who cannot tolerate the side effects of traditional antidepressants
• Patients whose depression is severe enough to significantly impair daily functioning

Contraindications

Ketamine is not appropriate for everyone. Contraindications include:

• Uncontrolled hypertension: Ketamine transiently raises blood pressure; uncontrolled hypertension increases cardiovascular risk
• Active psychotic disorders: History of psychosis or schizophrenia, as dissociative effects may worsen symptoms
• Active substance use disorders: Particularly alcohol or benzodiazepine dependence, due to interaction risks
• Unstable cardiovascular disease: Recent heart attack, unstable angina, or aortic aneurysm
• Pregnancy: Insufficient safety data for use during pregnancy
• Increased intracranial pressure: Conditions involving elevated ICP, such as untreated hydrocephalus
• Known allergy to ketamine: Rare, but an absolute contraindication

Important Safety Notes

While ketamine has a well-established safety profile as an anesthetic for over 50 years, its use for depression involves careful consideration:

• All treatments should be administered by a trained medical professional in a clinical setting
• Patients should be monitored during and after treatment
• Ketamine has potential for misuse; responsible prescribing practices are essential
• Regular follow-up with your prescribing physician and therapist is recommended
• Some researchers advocate combining ketamine with psychotherapy to enhance and extend benefits

Cost and Insurance

Typical Costs

Ketamine therapy for depression is a significant financial investment. Current pricing includes:

• IV ketamine infusions: $400-$800 per session; initial series of 6 infusions costs $2,400-$4,800
• Spravato (esketamine): $590-$885 per session at list price; insurance may cover most or all of the cost
• Maintenance infusions: $400-$800 every 2-6 weeks after the initial series
• Consultation and evaluation: $150-$350 for the initial assessment

Insurance Coverage

Insurance coverage varies significantly:

• Spravato is often covered by insurance, as it is FDA-approved for TRD. Prior authorization is typically required, and patients must have documented failure of at least two antidepressants
• IV ketamine is rarely covered by insurance, as it is used off-label. Some exceptions exist, and coverage is gradually expanding
• HSA and FSA accounts can typically be used for ketamine therapy
• Many clinics offer payment plans to make treatment more accessible

See our complete guide to ketamine costs and insurance

Finding a Provider

Choosing the right ketamine provider is one of the most important decisions in your treatment journey. Look for clinics that offer:

• Board-certified physicians (anesthesiologists, psychiatrists, or emergency medicine physicians) administering treatment
• Comprehensive screening before starting therapy
• Continuous vital sign monitoring during infusions
• Post-treatment observation periods
• Integration support or referrals to therapists experienced with ketamine-assisted therapy
• Transparent pricing with no hidden fees

Our directory helps you find verified ketamine clinics near you, complete with provider credentials, treatment offerings, patient reviews, and pricing transparency.

Find a ketamine clinic near you

Depression is a treatable medical condition. If you are experiencing thoughts of suicide, please call the 988 Suicide and Crisis Lifeline (call or text 988) or go to your nearest emergency room immediately. Ketamine may offer rapid relief, but in a crisis, please seek help now.